RHBDD2

Across TCGA pan-cancer cohorts, RHBDD2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RHBDD2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RHBDD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RHBDD2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where RHBDD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RHBDD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−1.001	<.001	12	view →
COAD	Female	III,IV	+0.371	<.001	8	view →
LUAD	Female	All	+0.378	<.001	5	view →
HNSC	Male	II,III,IV	+0.212	.033	4	view →
OV	All	All	+0.919	.004	2	view →
LSCC	All	All	+0.191	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RHBDD2–CCRCC

Open the CCRCC breakdown →